Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.

ABSTRACT: Colorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death worldwide, urging the need for new and more efficient therapeutic approaches. Ruthenium complexes have emerged as attractive alternatives to traditional platinum-based compounds in the treatment of CRC. This work aims to evaluate anti-CRC properties, as well as to identify the mechanisms of action of ruthenium complexes with the general formula [Ru(η⁵-C₅H₄R)(PPh₃)(4,4'-R'-2,2'-bipyridine)][CF₃SO₃], where R = CH₃, CHO or CH₂OH and R' = H, CH₃, CH₂OH, or dibiotin ester. The complexes (Ru 1-7) displayed high bioactivity, as shown by low IC₅₀ concentrations ag

SUBMITTER: Teixeira-Guedes C 

PROVIDER: S-EPMC9228117 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature